Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 May 20;50(1):103.
doi: 10.1186/s13052-024-01662-5.

Activated phosphoinositde 3-kinase (PI3Kδ) syndrome: an Italian point of view on diagnosis and new advances in treatment

Vassilios Lougaris  1 , Federico Le Piane  2 , Caterina Cancrini  3   4 , Francesca Conti  5 , Alberto Tommasini  6   7 , Raffaele Badolato  8 , Antonino Trizzino  9 , Marco Zecca  10 , Antonio De Rosa  11 , Federica Barzaghi  12 , Claudio Pignata  13
Affiliations
Review

Activated phosphoinositde 3-kinase (PI3Kδ) syndrome: an Italian point of view on diagnosis and new advances in treatment

Vassilios Lougaris et al. Ital J Pediatr. .

Abstract

Activated phosphoinositide 3-kinase (PI3Kδ) Syndrome (APDS) is an inborn error of immunity (IEI) with a variable clinical presentation, characterized by infection susceptibility and immune dysregulation that may overlaps with other Primary Immune Regulatory Disorders (PIRDs). The rarity of the disease, its recent discovery, and the multiform /multifaced clinical presentation make it difficult to establish a correct diagnosis, especially at an early stage. As a result, the true prevalence of the pathology remains unknown. There is no treatment protocol for APDS, and drug therapy is primarily focused on treating symptoms. The most common therapies include immunoglobulin replacement therapy, antimicrobial prophylaxis, and immunosuppressive drugs. Hematopoietic stem cell transplantation (HSCT) has been used in some cases, but the risk-benefit balance remains unclear. With the upcoming introduction of specific medications, such as selective inhibitors for PI3Kδ, clinicians are shifting their attention towards target therapy.This review provides a comprehensive overview of APDS with a focus on diagnostic and treatments procedures available. This review may be useful in implementing strategies for a more efficient patients' management and therapeutic interventions.Main Text.

Keywords: APDS; EBV; ESID; IEI; Leniolisib; Lymphoma; NGS; PI3Kδ; Sirolimus.

PubMed Disclaimer

Conflict of interest statement

Authors VL, CC, FC, AT, ATr, MZ, FB, CP received an honorarium from Pharming Group.

The other authors declare that they have no competing interests.

References

    1. Moriya K, Mitsui-Sekinaka K, Sekinaka Y, Endo A, Kanegane H, Morio T, et al. Clinical practice guideline for activated phosphatidyl inositol 3-kinase-delta syndrome in Japan. Immunological Med 2 Ottobre. 2023;46(4):153–7. doi: 10.1080/25785826.2023.2210366. - DOI - PubMed
    1. Vanselow S, Wahn V, Schuetz C. Activated PI3Kδ syndrome – reviewing challenges in diagnosis and treatment. Front Immunol [Internet] 2023 doi: 10.3389/fimmu.2023.1208567. - DOI - PMC - PubMed
    1. Michalovich D, Nejentsev S. Activated PI3 kinase Delta Syndrome: from Genetics to Therapy. Front Immunol. 2018;9:369. doi: 10.3389/fimmu.2018.00369. - DOI - PMC - PubMed
    1. Dornan GL, Siempelkamp BD, Jenkins ML, Vadas O, Lucas CL, Burke JE. Conformational disruption of PI3Kδ regulation by immunodeficiency mutations in PIK3CD and PIK3R1. Proc Natl Acad Sci U S 21 Febbraio. 2017;114(8):1982–7. doi: 10.1073/pnas.1617244114. - DOI - PMC - PubMed
    1. Maccari ME, Wolkewitz M, Schwab C, Lorenzini T, Leiding JW, Aladjdi N, et al. Activated phosphoinositide 3-kinase δ syndrome: update from the ESID Registry and comparison with other autoimmune-lymphoproliferative inborn errors of immunity. J Allergy Clin Immunol Ottobre. 2023;152(4):984–e99610. doi: 10.1016/j.jaci.2023.06.015. - DOI - PubMed

MeSH terms

Substances

Supplementary concepts